Orion Biotechnology

Biotechnology

Orion Biotechnology is a clinical stage company discovering and developing next-generation G Protein-Coupled Receptor (GPCR)-targeted therapeutics for the treatment of cancer and other serious diseases.  Orion’s novel drug modality involves precision engineering ligands of peptide and protein GPCRs to develop analogs with significant advantages over small molecule and antibody approaches.

Cantilever owns preferred shares in this company. 

www.orionbiotechnology.com